News ArticleConcord Biotech Reports 25% Revenue Growth in Q2 FY 2027 with Broad Product and Geographic Expansion
Receives ANDA approvals, completes USFDA facility inspection, launches dermatology division, and declares 1:1 bonus issue
Concord Biotech Limited announced a 25% year-on-year revenue increase for Q2 FY 2027 and 26% growth for H1 FY 2027, driven by broad strength across immunosuppressants, anti-infectives, antifungal and oncology product segments. The company received key ANDA approvals, completed USFDA inspection of its formulation facility, launched a dermatology division, and declared a 1:1 bonus issue to shareholders.
Concord Biotech Limited
Earnings Call Transcript
Concord Biotech Limited posted a 25% year-on-year revenue growth in Q2 FY 2027 and 26% growth for the first half, underpinned by strong performance across all product categories and geographies.
The company’s immunosuppressants segment delivered high double-digit growth, while anti-infectives and antifungal segments grew in line with overall company averages. Notably, the oncology segment almost doubled compared to the same quarter last year, demonstrating diversified product momentum.
During H1 FY 2027, Concord received ANDA approvals for Tofacitinib and Mycophenolate Mofetil Oral Suspension, enhancing its formulation portfolio, and filed a Drug Master File for Fidaxomicin in the US market to expand API opportunities.
Concord successfully completed the USFDA inspection of its Unit-II formulation facility at Valthera, Ahmedabad, and received ANVISA approval for its Unit-III facility at Limbasi, reinforcing its capabilities in regulated markets.
The company also launched 'Inspira', its dermatology division, marking a strategic expansion into science-led skin health treatments.
A 1:1 bonus issue was approved by shareholders, reflecting confidence in sustained growth and value creation.
Highlights
- Q2 FY 2027 revenue up 25% year-on-year; H1 FY 2027 revenue up 26%
- Immunosuppressants segment shows high double-digit growth; oncology segment nearly doubles
- ANDAs approved for Tofacitinib and Mycophenolate Mofetil Oral Suspension
- USFDA inspection cleared for Unit-II formulation facility; ANVISA approval for Unit-III
- Launch of Inspira dermatology division to diversify offerings
- Shareholders approve 1:1 bonus share issue to be implemented shortly
Key Data Snapshot
What happened
- Concord Biotech achieved a 25% revenue increase in Q2 FY 2027 and 26% for H1 FY 2027.
- Revenue growth was broad-based across all product segments—immunosuppressants, anti-infectives, antifungal, and oncology—and geographies.
- Oncology business nearly doubled compared to the previous year.
- Domestic API business grew by 42%, export revenue up by 8%.
Key details
- Received ANDA approvals for Tofacitinib and Mycophenolate Mofetil Oral Suspension, enhancing the formulation portfolio.
- Filed a US Drug Master File for Fidaxomicin to expand API opportunities in the US market.
- Successfully completed USFDA inspection of Unit-II formulation facility at Valthera, Ahmedabad.
- Received ANVISA approval for Unit-III facility at Limbasi, enhancing capabilities in regulated markets.
- Launched Inspira, a dermatology division focusing on science-led skin health solutions.
- Shareholders approved a 1:1 bonus share issue to be implemented soon.
Financial performance
- Gross margin declined by about 400 basis points year-on-year due to higher raw material and power costs influenced by geopolitical and supply chain factors.
- Margins impacted partly offset by renewable energy investments; full-year margin recovery expected through revenue growth and cost optimization.
- Q2 FY 2027 EBITDA margins reported at 33.8%.
Highlights
- Q2 FY 2027 revenue up 25% year-on-year; H1 FY 2027 revenue up 26%
- Immunosuppressants segment shows high double-digit growth; oncology segment nearly doubles
- ANDAs approved for Tofacitinib and Mycophenolate Mofetil Oral Suspension
- USFDA inspection cleared for Unit-II formulation facility; ANVISA approval for Unit-III
- Launch of Inspira dermatology division to diversify offerings
- Shareholders approve 1:1 bonus share issue to be implemented shortly
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Earnings Call Transcript
View allLatest corporate announcements and market updates in Earnings Call Transcript.
Dhoot Transmission Limited Shares Audio Recording of Q2 FY2026-27 Earnings Call Covering Unaudited Financial Results
Dhoot Transmission Limited has made the audio recording of its Q2 FY2026-27 earnings call available, covering unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Read Full Story
Max Healthcare Institute Limited Publishes Audio Recording of Q2 and H1 FY2026 Earnings Call
Max Healthcare Institute Limited released the audio recording of its earnings call held on November 3, 2026, which discussed the financial results for the quarter and half year ended September 30, 2026.
Read Full Story
Bajaj Finserv Limited Conducts Q2 and H1 FY2026 Earnings Call on 3 November with Presentation and Audio Available
Bajaj Finserv Limited held its scheduled earnings conference call on 3 November 2026 to discuss financial results for the quarter and half year ended 30 September 2026, providing detailed updates to investors and analysts.
Read Full Story
